KoBioLabs Inc
KoBioLabs, Inc. provides microbiome therapeutics for metabolic, immune, and brain diseases. The company was founded in 2014 and is based in Seoul, South Korea.
KoBioLabs Inc (348150) - Net Assets
Latest net assets as of September 2025: ₩49.99 Billion KRW
Based on the latest financial reports, KoBioLabs Inc (348150) has net assets worth ₩49.99 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩93.82 Billion) and total liabilities (₩43.82 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩49.99 Billion |
| % of Total Assets | 53.29% |
| Annual Growth Rate | N/A |
| 5-Year Change | -31.54% |
| 10-Year Change | N/A |
| Growth Volatility | 39.13 |
KoBioLabs Inc - Net Assets Trend (2018–2024)
This chart illustrates how KoBioLabs Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for KoBioLabs Inc (2018–2024)
The table below shows the annual net assets of KoBioLabs Inc from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩37.92 Billion | -38.66% |
| 2023-12-31 | ₩61.82 Billion | -20.05% |
| 2022-12-31 | ₩77.32 Billion | -14.64% |
| 2021-12-31 | ₩90.59 Billion | +63.54% |
| 2020-12-31 | ₩55.39 Billion | +203.29% |
| 2019-12-31 | ₩-53.62 Billion | -351.46% |
| 2018-12-31 | ₩-11.88 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to KoBioLabs Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 15559308554000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩9.69 Billion | 25.55% |
| Other Components | ₩196.36 Billion | 517.83% |
| Total Equity | ₩37.92 Billion | 100.00% |
KoBioLabs Inc Competitors by Market Cap
The table below lists competitors of KoBioLabs Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Clal Insurance Enterprises Holdings Ltd
TA:CLIS
|
$43.39 Million |
|
Accelya Solutions India Limited
NSE:ACCELYA
|
$43.42 Million |
|
Huxen Corp
TW:2433
|
$43.43 Million |
|
Prairie Operating Co.
F:7C5
|
$43.43 Million |
|
Globex Mining Enterprises Inc
OTCQX:GLBXF
|
$43.38 Million |
|
LHYFE S.A. EO -01
F:F1B
|
$43.38 Million |
|
Inission AB (publ)
ST:INISS-B
|
$43.37 Million |
|
Ihlas Gayrimenkul Proje Gelistirme ve Ticaret AS
IS:IHLGM
|
$43.35 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in KoBioLabs Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 44,950,617,800 to 37,919,018,430, a change of -7,031,599,370 (-15.6%).
- Net loss of 5,297,935,950 reduced equity.
- Share repurchases of 151,320,000 reduced equity.
- New share issuances of 151,320,000 increased equity.
- Other factors decreased equity by 1,733,663,420.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-5.30 Billion | -13.97% |
| Share Repurchases | ₩151.32 Million | -0.4% |
| Share Issuances | ₩151.32 Million | +0.4% |
| Other Changes | ₩-1.73 Billion | -4.57% |
| Total Change | ₩- | -15.64% |
Book Value vs Market Value Analysis
This analysis compares KoBioLabs Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.39x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | ₩-770.50 | ₩4680.00 | x |
| 2019-12-31 | ₩-3478.51 | ₩4680.00 | x |
| 2020-12-31 | ₩3569.33 | ₩4680.00 | x |
| 2021-12-31 | ₩5086.82 | ₩4680.00 | x |
| 2022-12-31 | ₩4613.94 | ₩4680.00 | x |
| 2023-12-31 | ₩2381.84 | ₩4680.00 | x |
| 2024-12-31 | ₩1957.23 | ₩4680.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently KoBioLabs Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -13.97%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -7.75%
- • Asset Turnover: 0.67x
- • Equity Multiplier: 2.69x
- Recent ROE (-13.97%) is above the historical average (-27.08%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -13064.31% | 0.01x | 0.00x | ₩-7.19 Billion |
| 2019 | 0.00% | -7643.57% | 0.02x | 0.00x | ₩-38.70 Billion |
| 2020 | -99.43% | -1199.45% | 0.08x | 1.06x | ₩-60.61 Billion |
| 2021 | -16.98% | -531.63% | 0.03x | 1.16x | ₩-24.44 Billion |
| 2022 | -28.35% | -188.89% | 0.09x | 1.60x | ₩-29.65 Billion |
| 2023 | -30.82% | -41.80% | 0.29x | 2.55x | ₩-18.35 Billion |
| 2024 | -13.97% | -7.75% | 0.67x | 2.69x | ₩-9.09 Billion |
Industry Comparison
This section compares KoBioLabs Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| KoBioLabs Inc (348150) | ₩49.99 Billion | 0.00% | 0.88x | $43.39 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |